MaxCyte, Inc. (NASDAQ:MXCT – Free Report) – William Blair lifted their FY2023 EPS estimates for MaxCyte in a research note issued to investors on Tuesday, December 12th. William Blair analyst M. Larew now forecasts that the company will post earnings per share of ($0.41) for the year, up from their prior forecast of ($0.45). William […]
Cell engineering technology specialist MaxCyte announced a significant chief executive transition on Tuesday and updated its revenue guidance for 2023.